Galantamine beneficial in mild-to-moderate AD

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1250, 2000-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Donepezil a smart choice for mild-to-moderate AD in the UK

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 603, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Salmeterol/fluticasone of value for mild-to-moderate asthma

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Salmeterol/fluticasone of value for mild-to-moderate asthma

Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer's Disease: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

By Aronson Stephen

Drugs & Aging, Vol. 26, Iss. 3, 2009-01 ,pp. : 231-239

Adis International

Access to resources Recommend Favorite

Galantamine treatment for AD warranted in Canada

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 339, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite